IceCure Showcases Innovative ProSense® Technology at the Breast Imaging Symposium in Colorado Springs
IceCure Medical's Presence at the Society of Breast Imaging Symposium
In a significant showcase of advanced medical technology, IceCure Medical Ltd. demonstrated its cutting-edge ProSense® cryoablation technology at the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium held from April 24 to April 27 in the picturesque Colorado Springs, Colorado. As a leader in developing minimally invasive cryoablation solutions for tumor destruction through freezing, IceCure is making notable strides in the fight against breast cancer.
The Symposium featured two sold-out breast cryoablation courses sponsored by IceCure, designed for radiologists looking to integrate ProSense® into their practices. These sessions, held on April 24 and 26, were part of a broader initiative by the SBI to familiarize medical professionals with innovative treatment options in breast imaging.
Hands-on Training and Expert Insight
Participants in the hands-on training courses were able to engage directly with the ProSense® system, benefiting from the guidance of experienced instructors. A significant highlight of the event was IceCure's VIP Exhibitor Hour, featuring Dr. Robert C. Ward, a recognized expert in women's imaging and breast cryoablation. Dr. Ward, who holds positions as an Assistant Professor at the Warren Alpert Medical School of Brown University and as the Program Director for the Breast Imaging Fellowship, provided invaluable insights into the clinical applications of ProSense®.
Dr. Ward’s contributions to the understanding of breast cryoablation highlight the efficacy of IceCure's technology. In particular, one of his recent publications in the American Journal of Roentgenology, titled 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials', has garnered attention for its focus on the clinical data supporting the use of cryoablation for breast cancer.
Addressing Breast Cancer with Precision
As cancer research continues to progress, the mission of IceCure aligns closely with that of the SBI, which emphasizes the importance of early detection and treatment to minimize the impact of breast cancer on patients’ lives. Eyal Shamir, IceCure’s Chief Executive Officer, remarked on the potential of ProSense® in improving patient outcomes: "Once diagnosed by radiologists, ProSense® can quickly and minimally invasively destroy tumors before they destroy lives. We were pleased to get ProSense® in front of thousands of SBI society physicians in the U.S., as we look ahead to potential regulatory clearance for breast cancer in the U.S."
Insights into the ProSense® System
The ProSense® Cryoablation System offers a unique approach to tumor treatment by utilizing liquid nitrogen to achieve rapid and effective tumor destruction for both benign and malignant lesions across various organ systems, notably breast, kidney, lung, and liver.
This innovative technology not only accelerates recovery times for patients but also reduces pain, surgical risks, and complications typically associated with traditional surgical procedures. Its portable design and liquid nitrogen use facilitate fast, office-based interventions that are transforming the treatment landscape for breast tumors.
The Future of IceCure Medical
As IceCure Medical continues to develop and market its advanced therapeutic solutions, the company remains focused on expanding the use of cryoablation in clinical practice. Their commitment to enhancing treatment strategies reflects a growing recognition of the technology's potential benefits, particularly in improving patients’ quality of life and treatment outcomes. With a strong emphasis on education and hands-on training, IceCure is not only advancing its mission but also shaping the future of breast cancer treatment through innovative solutions.
In conclusion, IceCure Medical’s robust presence at the SBI 2025 Breast Imaging Symposium is a testament to the ongoing demand for improved, less invasive treatment options in the field of oncology. As interest in cryoablation grows among healthcare professionals, the potential for significant advancements in breast cancer care becomes increasingly tangible. Expect to see more developments from IceCure in the coming years as they continue to advocate for better solutions for patients dealing with breast cancer.